Journal
NUTRIENTS
Volume 13, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/nu13010037
Keywords
microbiota; Alzheimer’ s disease; microbiota– gut– brain axis; neuroinflammation; probiotics
Categories
Funding
- European Regional Development Fund [01.2.2-LMT-K-718-02-0014]
- Research Council of Lithuania (LMTLT)
Ask authors/readers for more resources
Alzheimer's disease (AD) is reportedly the most frequent cause of dementia, with disturbances in the microbiota-gut-brain (MGB) axis potentially playing a crucial role in its development. Dysbiosis in gut microbiota and microbiota-host interactions could lead to neuroinflammation and neural injury in AD, suggesting new preventive and therapeutic approaches through microbiota modulation. Research on MGB involvement is considered vital for identifying new treatment targets and therapies for AD.
For years, it has been reported that Alzheimer's disease (AD) is the most common cause of dementia. Various external and internal factors may contribute to the early onset of AD. This review highlights a contribution of the disturbances in the microbiota-gut-brain (MGB) axis to the development of AD. Alteration in the gut microbiota composition is determined by increase in the permeability of the gut barrier and immune cell activation, leading to impairment in the blood-brain barrier function that promotes neuroinflammation, neuronal loss, neural injury, and ultimately AD. Numerous studies have shown that the gut microbiota plays a crucial role in brain function and changes in the behavior of individuals and the formation of bacterial amyloids. Lipopolysaccharides and bacterial amyloids synthesized by the gut microbiota can trigger the immune cells residing in the brain and can activate the immune response leading to neuroinflammation. Growing experimental and clinical data indicate the prominent role of gut dysbiosis and microbiota-host interactions in AD. Modulation of the gut microbiota with antibiotics or probiotic supplementation may create new preventive and therapeutic options in AD. Accumulating evidences affirm that research on MGB involvement in AD is necessary for new treatment targets and therapies for AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available